A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses. by nantkweststg | Feb 12, 2021
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. by nantkweststg | Feb 12, 2021
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist. by nantkweststg | Feb 12, 2021
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy. by nantkweststg | Feb 12, 2021
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells by nantkweststg | Jan 28, 2021
Recent Comments